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A B S T R A C T
Prostate cancer is a leading public health problem of male population in developed countries. Gold standard for pros-
tate cancer diagnosis is true cut biopsy guided by transrectal ultrasound1–5. Aim of this study was to determine sensitiv-
ity, specificity, accuracy, positive and negative predictive value of transrectal sonography (TRUS) in prostate cancer de-
tection. The analysis was made for two time periods, before and after routine implementation of prostate specific antigen
(PSA) in prostate cancer diagnostics. From 1984 to 1993 TRUS guided prostate biopsy was performed in 564, and from
1994 to 2008 in 5678 patients. In the second period PSA was routinely used in prostate cancer diagnostics. In the first pe-
riod by TRUS we have made an exact diagnosis of prostate cancer in 18.97% of patients what was confirmed by biopsy.
4.61% ware false positive and 11.34% ware false negative. In the second period prostate cancer was recognized in 30.34%
of patients, confirmed by biopsy. False positive cases ware 6.11% and false negative 29.31%. Sensitivity of transrectal
sonography in the first period was 62.57%, specificity 94.2%, accuracy 86.2%, positive predictive value 80.45% and nega-
tive predictive value 87.72%. In the second period sensitivity was 50.87%, specificity 91.93%, accuracy 73.84%, positive
predictive value 83.24% and negative predictive value 70.39%. Based on our experience we can conclude that prostate
cancer is mostly found in the peripheral zone. Smaller tumors are hipoechoic and bigger tumors are hiperechoic. Prostate
cancer lesions are impossible to differentiate from chronic prostatitis only by TRUS. Implementation of PSA has signifi-
cantly decrease sensitivity, accuracy and negative predictive value of TRUS in prostate cancer detection. TRUS guided
true cut biopsy is a gold standard in prostate cancer diagnostics.
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Introduction
Prostate cancer is a major public health problem fac-
ing man today in all the developed countries1,2. Prostate
cancer now outnumbers the lung cancer as the most
common cancer in American men1,2. The incidence of
prostate cancer is rapidly increasing in the Primorsko-
-Goranska County of Croatia2,3. Transrectal sonography
(TRUS) guided true cut biopsy is a gold standard in pros-
tate cancer diagnostics2,4–10. Ultrasound criteria to detect
and characterize suspicious lesions for prostate cancer
are controversial5,6. Sensitivity of TRUS in prostate can-
cer recognition is from 60–85%5–10. Retrospective studies
have shown that in 24–30% of pathohistologically proven
prostate cancer the ultrasonographic finding was not
uniform5–10. Most authors concord that the percentage of
false positive and false negative findings is too high5–10.
In 30% of cases there is an overlap between benign and
malignant lesions of the prostate5.
Low positive predictive value for the presence of pros-
tate cancer is the main weakness of TRUS5–10. To im-
prove the capability of TRUS to find prostate cancer le-
sions an implementation of color Doppler, contrast en-
hancement and elastography was suggested5,6. The re-
sults are not encouraging5,6. Several studies have shown
that taking the endosonographic morphology of the pros-
tate into consideration for biopsy strategies may improve
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the quality of the prostate biopsy5–10. Also, patients with
suspicious lesions detected by TRUS have a higher risk
of being diagnosed with prostate cancer5. A recent Ko-
rean study has shown that a scoring system for malig-
nancy prediction developed for the characteristics of fo-
cal suspicious lesions as depicted on TRUS can help
predict the outcome of TRUS guided biopsies5.
The aim of our study was to determine sensitivity,
specificity, accuracy, positive and negative predictive va-
lue of transrectal sonography (TRUS) in prostate cancer
detection at our Clinic in 25 years period.
Patients and Methods
This retrospective study was approved by our Institu-
tional Ethical Committee.
A total of 6,242 patients with or without prostate can-
cer who underwent systemic and targeted biopsies for
suspicious lesions were included in this study. Biopsies
were made by true cut method under transrectal sono-
graphy guidance. The TRUS guided biopsies were per-
formed by urologists with more than 10 years of experi-
ence in the field. During 25 years we used several ultra-
sound scanners for TRUS but they were all equipped
with a 4–9 MHz broadband curved array endocavitary
transducer. Tissue samples were pathohistologically ana-
lyzed to confirm or exclude the diagnosis of prostate can-
cer. Patients were divided in two groups according to two
time periods, before and after routine implementation of
prostate specific antigen (PSA) in prostate cancer diag-
nostics. From 1984 to 1993 TRUS guided prostate biopsy
was performed in 564, and from 1994 to 2008 in 5,678 pa-
tients. In the second period PSA was routinely used in
prostate cancer diagnostics.
Data Analysis
The data was elaborated and analyzed using Sta-
tistica 6.1 software package (StatSoft.lnc., Tulsa, OK,
USA). For each time period the sensitivity, specificity,
accuracy, positive and negative predictive value of trans-
rectal sonography was calculated using standard statis-
tical formulas. Statistic significance was calculated us-
ing chi-squared test and p<0.05 was considered signifi-
cant.
Results
In the first period by TRUS we have made an exact di-
agnosis of prostate cancer (Figure 1) in 18.97% (107) of
patients what was confirmed by biopsy. 4.61% (26) ware
false positive (Figure 2) and 11.34% (64) ware false nega-
tive. In the second period prostate cancer was recognized
in 30.34% (1723) of patients, confirmed by biopsy. False
positive cases ware 6.11% (347) and false negative
29.31% (1664). Sensitivity of transrectal sonography in
the first period was 62.57%, specificity 94.2%, accuracy
86.2%, positive predictive value 80.45% and negative pre-
dictive value 87.72%. In the second period sensitivity was
50.87%, specificity 91.93%, accuracy 73.84%, positive
predictive value 83.24% and negative predictive value
70.39%. Based on our experience prostate cancer is mos-
tly found in the peripheral zone (Figure 3). Smaller tu-
mors are hipoechoic and bigger tumors are hiperechoic.
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Fig. 1. Transrectal sonography showing two hipoechoic prostate
cancer lesions in the left prostatic lobe
Fig. 2. Transrectal sonography showing a false positive finding
in chronic prostatitis.
Fig. 3. Transrectal sonography showing a hipoechoic prostate
cancer lesion (arrow) in the peripheral zone of the right prostatic
lobe
Prostate cancer lesions are impossible to differentiate
from chronic prostatitis only by TRUS. Implementation
of PSA has significantly (p<0.05) decreased the sensitiv-
ity, accuracy and negative predictive value of TRUS in
prostate cancer detection.
Discussion and Conclusion
Our study has demonstrated that the sensitivity of
transrectal sonography in the first period was 62.57%,
specificity 94.2%, accuracy 86.2%, positive predictive va-
lue 80.45% and negative predictive value 87.72%. In the
second period sensitivity was 50.87%, specificity 91.93%,
accuracy 73.84%, positive predictive value 83.24% and
negative predictive value 70.39%. The results from our
study are consistent with findings of previous research.
Sensitivity of TRUS in prostate cancer recognition is
from 60–85 %5–10. Retrospective studies have shown that
in 24–30% of pathohistologically proven prostate cancer
the ultrasonographic finding was not uniform5–10. Most
authors concord that the percentage of false positive and
false negative findings is too high5–10. In 30% of cases
there is an overlap between benign and malignant le-
sions of the prostate5.
Low positive predictive value for the presence of pros-
tate cancer is the main weakness of TRUS5–10. Our find-
ings show that the implementation of PSA has signifi-
cantly (p<0.05) decreased the sensitivity, accuracy and
negative predictive value of TRUS in prostate cancer de-
tection, probably do to more TRUS examinations in
subclinical prostate cancers. In the first period PSA was
not implemented in routine urological practice, so the
majority of patients had a clinically manifested, advan-
ced prostate cancer par example: positive digitorectal ex-
amination, pelvic pain, hematuria etc.
We also concluded that in most cases smaller tumors
are hipoechoic and bigger tumors are hiperechoic. Pros-
tate cancer lesions are impossible to differentiate from
chronic prostatitis only by TRUS.
In conclusion transrectal sonography guided true cut
biopsy is a gold standard in prostate cancer diagnostics.
Only TRUS findings are not enough to make an accurate
diagnosis of prostate cancer.
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TRANSREKTALNI ULTRAZVUK U OTKRIVANJU KARCINOMA PROSTATE – NA[E 25-GODI[NJE
ISKUSTVO U KORI[TENJU
S A @ E T A K
Karcinom prostate je vode}i javno-zdravstveni problem mu{ke populacije u razvijenim zemljama. Klju~na dijagno-
sti~ka metoda u postavljanju kona~ne dijagnoze je biopsija prostate pod kontrolom tranrektalnog ultrazvuka. Cilj ove
studije bio je utvr|ivanje senzitivnosti, specifi~nosti, sigurnosti te pozitivne i negativne prediktivne vrijednosti trans-
rektalne sonografije u detekciji karcinoma prostate. Analiza je ra|ena u dva razdoblja ovisno o primjeni prostata spe-
cifi~nog antigena u dijagnostici karcinoma prostate. Od 1984. do 1993 godine biopsija prostate vo|ena transrektalnim
ultrazvukom u~injena je u 564, a od 1994. do 2008. godine u 5678 bolesnika. Od 1994. kao rutinska dijagnosti~ka
metoda kori{tena je i serumska koncentracija prostata specifi~nog antigena (PSA). U prvom razdoblju u 18.97% bo-
lesnika transrektalnom sonografijom postavili smo dijagnozu karcinoma prostate {to je potvr|eno biopsijom. La`no
pozitivnih bilo je 4.61%, a la`no negativnih 11.34%. U drugom razdoblju karcinom prostate prepoznat je u 30.34%
bolesnika {to je potvr|eno biopsijom. La`no pozitivnih bilo je 6.11%, a la`no negativnih 29.31%. Senzitivnost trans-
rektalne sonografije u prvom razoblju bila je 62.57%, specifi~nost 94.2%, sigurnost 86.2%, pozitivna prediktivna vrijed-
nost 80.45% te negativna prediktivna vrijednost 87.72%. U drugom razoblju senzitivnost je bila 50.87%, specifi~nost
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91.93%, sigurnost 73.84%, pozitivna prediktivna vrijednost 83.24% te negativna prediktivna vrijednost 70.39%. Te-
meljem na{eg iskustva mo`emo zaklju~iti kako se karcinom prostate otkriva uglavnom uz kapsulu. Mali tumori su
hipoehogeni dok su ve}i, uznapredovali hiperehogeni. Karcinom prostate nemogu}e je transrektalnom sonografijom
razlikovati od kroni~nog prostatitisa. Uporaba PSA smanjila je zna~ajno senzitivnost, sigurnost i negativnu predik-
tivnu vrijednost transrektalne sonografije u otkrivanju karcinoma prostate. Ultrazvu~no vo|ena transrektalna biopsija
prostate zlatni je standard u dijagnostici karcinoma prostate.
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